Drug intelligence / Profile preview

TreXTAM

Development stage
Preclinical
Lead developer
TherapyX
Modality
Nanoparticles → Drug Delivery Systems, Recombinant Proteins and Enzymes
Administration
Oral
01

Overview

TreXTAM is a microparticulate therapeutic candidate developed by TherapyX for the treatment of autoimmune diseases. Currently in the IND-enabling stage, TreXTAM is based on the company's TreX platform, which focuses on the induction and expansion of regulatory T cells (Tregs) to restore immune tolerance. The formulation utilizes TherapyX's proprietary microparticle technology—typically composed of poly(lactic-co-glycolic acid) (PLGA)—to deliver a combination of Treg-promoting cytokines, such as Transforming growth factor beta (TGF-beta) and Interleukin-2 (IL-2), alongside specific autoantigens (Targeted Antigenic Microparticles or TAM). This site-specific, controlled-release approach is designed to suppress pathogenic immune responses while avoiding the systemic toxicity associated with high-dose cytokine therapy.

Other names
TreX-TAM
02

Targets

TGFBR (TGF-beta receptor)RARA (Retinoic acid receptor alpha)

Beyond the preview

Go deeper on TreXTAM.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on TreXTAM.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call